Dive deeper

Open any topic for the full explanation, tables, clinical checkpoints, and references.

Full-length video Where can I learn more about what to expect from a skin biopsy?

A complete visual guide

Watch the full explanation on YouTube A complete visual review with the supporting clinical context.
What does a skin biopsy actually sample?

Direct Answer: A Biopsy Is a Sampling Strategy

A dermatologist can learn a great deal by looking at and touching a skin lesion. Some diagnoses, however, cannot be made reliably from appearance alone. A biopsy supplies the missing information by allowing a physician who specializes in pathology to examine the tissue under a microscope.1,2

The important word is sample.

A biopsy may remove the entire visible lesion, or it may take only the part most likely to answer the question. That is not a shortcut. It is often the correct design. A large lesion on the face, for example, may need only a representative sample before treatment is planned. A small suspicious pigmented lesion may be removed completely with a narrow diagnostic margin so its full depth and architecture can be evaluated.2,3

Think of a biopsy as taking a core sample from the ground before building a foundation. The goal is not to excavate the whole property. The goal is to learn what is underneath so the next decision is based on evidence rather than appearance alone.

Why would a dermatologist recommend a skin biopsy?

Why Would a Dermatologist Recommend a Biopsy?

A biopsy can help distinguish among:

  • a benign growth and a skin cancer;
  • basal cell carcinoma, squamous cell carcinoma, melanoma, or another tumor;
  • a superficial tumor and one that extends deeper;
  • different microscopic patterns that can look similar during an examination.

The result may be a single diagnosis. It may also describe a microscopic pattern, list a short differential diagnosis, or recommend correlation with the clinical appearance. That last outcome does not mean the biopsy was useless. Some skin diseases are solved by connecting three sources of information: what the patient reports, what the dermatologist sees, and what the pathologist sees under the microscope.2,4

How is the biopsy type chosen?

How Is the Biopsy Type Chosen?

The dermatologist works backward from the question:

  1. What diagnosis is being considered?
  2. Does depth matter?
  3. Does the pathologist need the full architecture of the lesion?
  4. Is the spot small enough to remove completely for diagnosis?
  5. Is the location one where a larger diagnostic procedure would create unnecessary risk or scarring?

No technique wins every time. A shallow sample can be exactly right for a clearly superficial process and exactly wrong when tumor depth determines staging. A narrow full-thickness core can be ideal for a rash yet miss a focal aggressive area inside a broad, mixed tumor.2,5

Common Skin-Biopsy Techniques

Common approaches are summarized below. The right choice depends on the lesion, location, and diagnostic question.1,2,5

Common Skin-Biopsy Techniques
TechniqueWhat it samplesWhy it may be selectedUsual closureImportant limitation
Superficial shaveThe top layers of skinA raised or clearly superficial processUsually heals without stitchesMay be too shallow when invasion depth matters
Deep shave or saucerizationA broader, bowl-shaped sample extending deeper into the dermisA lesion that needs both width and depth without an elliptical incisionOften heals without stitches; varies by size and siteMust not be confused with a superficial shave
PunchA small round core, often through the full thickness of skinWhen architecture or depth is importantMay be left open or closed with stitchesA small core can miss a different area within a mixed lesion
Incisional biopsyA representative portion of a larger or deeper lesionA lesion that is too large or poorly positioned for complete diagnostic removalUsually closed with stitchesIntentionally does not sample the whole lesion
Excisional biopsyThe entire visible lesion with a narrow diagnostic marginWhen complete assessment is feasible, especially for a suspicious melanocytic lesionUsually closed with stitchesDiagnostic removal may still not be definitive cancer treatment

The names can be confusing because shave describes a family of techniques. A superficial shave and a deep saucerization are not the same operation. What matters is not the label alone, but the depth and shape of the tissue actually collected.3,5

What changes when melanoma is a concern?

What If Melanoma Is a Concern?

When melanoma is suspected, the preferred diagnostic goal is usually to remove the entire suspicious lesion with a narrow margin and enough depth to avoid cutting through the base, when that can be done safely and reasonably. This may be accomplished with an elliptical excision, a punch excision for a small lesion, or a properly performed deep saucerization.3

A superficial shave is generally avoided when it could prevent accurate measurement of melanoma depth. That measurement, called Breslow thickness, helps guide staging and later treatment.

Complete diagnostic sampling is not always practical. A very large lesion or one on the face, ear, palm, sole, digit, or another difficult site may be sampled partially. AAD melanoma guidance recognizes those exceptions. A partial biopsy does not mean that cancer was spread by the procedure; the concern is whether the sample provides enough information for diagnosis and accurate depth or staging information.3,6,7

Evidence in numbersEvidence in Numbers: A Partial Sample Can Change the Measured Stage

Evidence in Numbers: A Partial Sample Can Change the Measured Stage

In an Australian registry study of 175 invasive melanomas diagnosed by shave biopsy, 54% were transected at the base. Residual melanoma was found in 69% of those transected tumors, and 12% of the full 175-case group was assigned a higher T category after the remaining tumor was removed.7

That does not make every shave biopsy inappropriate. It shows why a superficial shave is a poor match when melanoma depth may determine staging, while a properly performed deep saucerization can be a different operation entirely.

What happens during a skin-biopsy appointment?

What Happens During the Appointment?

Although details vary, the sequence is usually simple.

1. The lesion and site are confirmed

The dermatologist identifies the area, reviews the reason for biopsy, and chooses the portion most likely to answer the question. A photograph or site map may be taken so the exact location can be found again after the skin heals.

2. The skin is cleaned and numbed

Local anesthetic is injected into the skin. The injection can sting or burn briefly. Once the anesthetic has taken effect, the tissue sampling should not feel sharp; most patients feel pressure or movement instead.8

Tell the clinician if you still feel pain. More anesthetic can usually be given.

Evidence in numbersEvidence in Numbers: The Injection Is Usually the Uncomfortable Part

Evidence in Numbers: The Injection Is Usually the Uncomfortable Part

In a prospective dermatologic-surgery study, 88.5% of patients noticed pain from the numbing injection, but 112 of 120 patients, or 93.3%, reported no pain during the procedure after anesthesia took effect.8 This was a dermatologic-surgery cohort rather than a biopsy-only study, but it matches the practical sequence patients usually experience: a brief sting, then pressure rather than sharp pain.

In a separate single-center series of 1,294 punch biopsies, postoperative bleeding was recorded in 0.9% and infection in 0.2%.15 Those rates apply to that punch-biopsy setting, not every technique or body site.

3. The tissue is collected

The dermatologist uses the selected technique to obtain the specimen. The tissue-removal portion commonly takes only minutes, although preparation, bleeding control, photographs, labeling, and closure add time.1,5

4. Bleeding is controlled and the site is closed if needed

A superficial shave or many saucerization sites can heal without stitches. Punch, incisional, and excisional biopsy sites may be closed with one or more stitches, depending on their size, depth, location, and tension. There is no universal stitch rule that fits every site.

5. The specimen is sent to pathology

The specimen is placed in a labeled container and sent with clinical information. The pathologist processes thin sections, examines them under a microscope, and may order deeper sections, special stains, or consultation when the first view does not fully answer the question.2,4

What can a skin biopsy show?

What Can a Biopsy Show?

Depending on the diagnosis, the report may identify:

  • the type of lesion or cancer;
  • a microscopic subtype or growth pattern;
  • the depth or thickness present in the sample;
  • features that make a tumor lower risk or higher risk;
  • whether the process reaches an examined edge of the specimen;
  • whether additional testing or another sample is needed.

The next article in this journey, What Does My Skin Biopsy Report Mean?, explains those terms in detail.

What can a partial biopsy miss?

What Can a Partial Biopsy Miss?

A lesion can be heterogeneous: one part may look different from another under the microscope. A partial biopsy samples one location at one moment. It can establish the diagnosis and still miss:

  • a deeper focus;
  • a more aggressive growth pattern elsewhere in the lesion;
  • the maximum thickness of a melanoma;
  • an area that better explains why the clinical appearance seemed unusual.

That limitation does not make partial biopsy bad. It explains why the dermatologist chooses the site and depth deliberately, and why the treatment plan may need to change if later tissue shows a deeper or different component.2,3,6,7

“The best biopsy is not the biggest biopsy. It is the smallest biopsy that reliably answers the question without sacrificing information the next decision will need.”

- Dr. Hocker
Does a positive biopsy edge mean something went wrong?

Does a Positive Biopsy Edge Mean Something Went Wrong?

Usually, no.

For a BCC biopsy, positive margin, involved margin, or transected means tumor reaches an examined edge of the biopsy specimen. That is common when the biopsy was intentionally diagnostic rather than a definitive cancer-removal operation. It does not mean the biopsy failed. Other diagnoses can give the same margin phrase a different consequence, so the next step depends on the exact diagnosis and treatment plan.9

The reverse is more important: a negative or clear margin on a diagnostic BCC or cSCC biopsy cannot be relied upon to prove that the cancer is gone. The biopsy's first job is diagnosis. Definitive treatment planning follows the diagnosis, not reassurance from the biopsy-margin line.13,14

Evidence in numbersEvidence in Numbers: Clear on Biopsy Is Not the Same as Cancer Cleared

Evidence in Numbers: Clear on Biopsy Is Not the Same as Cancer Cleared

A literature review combined 221 keratinocyte carcinomas reported with negative biopsy margins. Subsequent analysis still found tumor in 55 cases, or 24.9% overall: 27.5% of BCCs and 12.8% of cSCCs.13

In another study, deeper sections changed 11 of 47 initially negative shave-biopsy margins to positive: 30% of BCCs and 15% of cSCCs.14 The practical conclusion is categorical even though the exact percentages vary: a diagnostic biopsy-margin result is not an adequate test of cancer clearance.

When might a spot be observed instead of biopsied?

When Might a Spot Be Observed Instead of Biopsied?

Not every spot needs immediate surgery or biopsy. After examining a flat, mildly atypical melanocytic lesion without specific melanoma features, a dermatologist may recommend short-term photographic or dermoscopic monitoring when a reliable follow-up plan exists.12

Observation is not a home diagnosis. The clinician selects the lesion and follow-up interval; change during monitoring should trigger re-evaluation and may prompt biopsy. Patients should not choose monitoring by matching a photograph online.12

What happens after the biopsy result?

What Happens After the Biopsy?

Three plans should be clear before you leave:

  1. Site care: Follow the instructions from the treating office. Dressing, ointment, activity, showering, and stitch-removal directions depend on the biopsy type and body site. Contact the treating office if redness, swelling, or drainage is increasing rather than improving.1
  2. Result communication: Ask how the office will contact you and what to do if you have not heard by the expected time. Processing time varies, especially when extra stains or consultation are needed.4,11
  3. Next decision: A benign result may end the workup. A cancer diagnosis leads to a diagnosis-specific treatment decision based on the exact cancer, risk features, location, and patient.

Some scar is expected after any procedure that removes skin. Its size and appearance depend on the depth, location, closure, skin tension, and individual healing.1

What should I ask before leaving a biopsy visit?

Questions to Ask Before You Leave

  • What diagnosis are you trying to confirm or exclude?
  • Which biopsy technique are you planning, and why does it fit this lesion?
  • Is the biopsy intended to sample the lesion or remove the visible lesion completely?
  • Will I have stitches?
  • How should I care for this specific site?
  • How and when will the result be communicated?
  • If the pathology does not match the clinical appearance, what happens next?
Frequently asked questions about skin biopsies

Frequently Asked Questions

Can a skin biopsy spread cancer?

Routine skin-biopsy techniques are standard diagnostic procedures. For melanoma, evidence reviewed in clinical guidance does not show that an appropriately selected partial biopsy worsens recurrence or sentinel-node outcomes. The practical issue is not spreading the cancer; it is collecting enough tissue for an accurate diagnosis and depth assessment.3

Why did my dermatologist perform a shave instead of a punch?

Because the shape of the sample should match the lesion and the question. A broad deep saucerization may capture more of a pigmented lesion than a narrow punch. A punch may be better when full-thickness architecture in a small area is important. The word shave alone does not tell you how deep the biopsy was.

Does an excisional biopsy mean the cancer has been fully treated?

Not necessarily. Excisional biopsy describes a diagnostic removal of the visible lesion. Definitive cancer treatment may require a different margin, mapped margin assessment, additional staging, or another procedure after the diagnosis is known.3,9

Why would the pathology laboratory need more time?

Some specimens require deeper sections, special laboratory tests, comparison with prior material, or another pathologist's review. A longer interval does not by itself mean the result is worse.4,11

Will every biopsy leave a scar?

Yes, some scar is expected whenever skin is removed. The final appearance varies substantially by technique, location, depth, closure, and the way an individual heals.1

What if the pathology result does not make sense to my dermatologist?

The treating dermatologist may speak with the pathologist, provide additional clinical information or photographs, request deeper sections or expert review, or obtain another sample. The next Patient Journey guide explains when skin pathology should get a second opinion.

Where should I go next in the Patient Journey?

Next Steps in the Patient Journey

  • Already have your result? Read What Does My Skin Biopsy Report Mean?
  • The result and the examination do not match? Read When Should Skin Pathology Get a Second Opinion?
  • The biopsy shows cancer? Move to the treatment-options page for basal cell carcinoma, squamous cell carcinoma, melanoma, or the diagnosed rare tumor.

Talk with your dermatologist about what the biopsy was designed to answer and what the result changes. Use the treating office's instructions for the biopsy site rather than generic wound-care advice.

Continue with the question that fits you now

Who reviewed and authored this biopsy guide?
Portrait of Dr. Thomas L.H. Hocker

About the Author

Dr. Thomas L.H. Hocker is a Harvard- and Mayo Clinic-trained, triple board-certified dermatologist, Mohs surgeon, and dermatopathologist. He is the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health and an Iron Surgeon lecturer at the American Society for Dermatologic Surgery. His work focuses on Mohs surgery for melanoma, complex and rare skin tumors, and aesthetic reconstruction after skin-cancer treatment. He co-authored the best-selling textbook Review of Dermatology and created Skin Trust to give patients and clinicians free access to clear, current, evidence-based education.

Read Dr. Hocker's background and mission

Dr. Hocker earned his bachelor's degree with honors from Yale University, where he was inducted into Phi Beta Kappa. As a Winston Churchill Scholar, he then studied at the University of Cambridge and earned an M.Phil. in Organic Chemistry. He received his M.D. with honors from Harvard Medical School, where his research focused on melanoma genetics. He completed dermatology residency at Mayo Clinic, a dermatopathology fellowship at the University of Michigan, and a Mohs micrographic and reconstructive surgery fellowship at Mayo Clinic. He is board-certified in Dermatology, Dermatopathology, and Mohs Micrographic Surgery.

Dr. Hocker serves as the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health. He is an internationally invited lecturer and speaker who teaches about Mohs surgery for melanoma, complex and rare tumors, dermatopathology, and aesthetic reconstruction after skin-cancer treatment. He has also been selected as an Iron Surgeon lecturer by the American Society for Dermatologic Surgery. He is the co-author of Review of Dermatology, a best-selling dermatology review textbook, and he continues to teach and mentor medical students, residents, and physicians.

Skin Trust exists because Dr. Hocker believes access to excellent medical knowledge should not depend on geography, wealth, or proximity to a major academic center. After training at several of the world's leading institutions, he sees that education as both a gift and a responsibility: to translate current evidence, expert judgment, and hard-won clinical experience into guidance that patients, families, and clinicians can actually use.

The mission is to increase awareness, reduce avoidable suffering, and give every person equal access to trustworthy, up-to-date information that can help them make the best decisions for their life. Skin Trust also extends Dr. Hocker's lifelong commitment to teaching, writing, and mentoring medical students and residents as they build lives and careers of purpose and service.

For Dr. Hocker, this work is also an expression of faith. He regards the opportunities to learn at Yale, Cambridge, Harvard, Mayo Clinic, and the University of Michigan as blessings from God. Teaching, writing, mentoring, and building Skin Trust are ways to pay those blessings forward in service to patients, learners, and the broader community. His faith is the personal motivation to do this work carefully, generously, and with integrity; it is not a condition of using or benefiting from this free resource.

View Review of Dermatology Read Dr. Hocker's full biography
References for this skin-biopsy guide

References

  1. National Library of Medicine. Skin Biopsy. MedlinePlus. Updated 2022.
  2. Sleiman R, Kurban M, Abbas O. Maximizing diagnostic outcomes of skin biopsy specimens. Int J Dermatol. 2013;52:72-78. PMID: 23278612.
  3. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250. DOI: 10.1016/j.jaad.2018.08.055. PMID: 30392755.
  4. Trotter MJ, Au S, Naert KA. Practical strategies to improve the clinical utility of the dermatopathology report. Arch Pathol Lab Med. 2016;140:759-765. PMID: 27472234.
  5. Pickett H. Shave and punch biopsy for skin lesions. Am Fam Physician. 2011;84:995-1002. PMID: 22046939.
  6. Ng JC, Swain S, Dowling JP, et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma. Arch Dermatol. 2010;146:234-239. DOI: 10.1001/archdermatol.2010.14. PMID: 20231492.
  7. de Menezes SL, Kelly JW, Wolfe R, Farrugia H, Mar VJ. The increasing use of shave biopsy for diagnosing invasive melanoma in Australia. Med J Aust. 2019;211:213-218. PMID: 31328802.
  8. Beqqal K, Debie J, Constantin S, et al. Evaluation of local anesthesia and pain control in dermatological surgery: a prospective study of 120 patients. Eur J Dermatol. 2010;20(3):349-353. DOI: 10.1684/ejd.2010.0925. PMID: 20299308.
  9. National Comprehensive Cancer Network. Basal Cell Skin Cancer. Version 2.2026.
  10. Koslosky CL, El Tal AK, Workman B, et al. Reliability of skin biopsies in determining accurate tumor margins: a retrospective study after Mohs micrographic surgery. Dermatol Surg. 2014;40:964-970. DOI: 10.1097/01.DSS.0000452621.79017.19. PMID: 25099294.
  11. Zembowicz A, Ahmad A, Lyle SR. A comprehensive analysis of a web-based dermatopathology second opinion consultation practice. Arch Pathol Lab Med. 2011;135:379-383. PMID: 21366464.
  12. Kashani-Sabet M, Leachman SA, Stein JA, et al. Early detection and prognostic assessment of cutaneous melanoma: consensus on optimal practice and the role of gene expression profile testing. JAMA Dermatol. 2023. PMID: 36920356. DOI: 10.1001/jamadermatol.2023.0127.
  13. Purnell JC, Duncan JR, Stratton MS, Huang C, Phillips CB. Negative predictive value of biopsy margins in keratinocyte carcinoma: a literature review. Dermatol Surg. 2020;46(4):525-529. DOI: 10.1097/DSS.0000000000002171. PMID: 31567613.
  14. Schnebelen AM, Gardner JM, Shalin SC. Margin status in shave biopsies of nonmelanoma skin cancers: is it worth reporting? Arch Pathol Lab Med. 2016;140(7):678-681. DOI: 10.5858/arpa.2015-0313-OA. PMID: 27116089.
  15. Yasui Y, et al. Complications and risk factors of punch biopsy: a retrospective large-scale study. J Dermatol. 2023;50(1):98-101. DOI: 10.1111/1346-8138.16585. PMID: 36151785.